Aging
Navigate
Submit an Article
Research Paper|Volume 12, Issue 20|pp. 20835–20861
SMARCD3 is a potential prognostic marker and therapeutic target in CAFs
Back to articleFigure 2(2 of 9)
100%
Figure 2
Figure 2.Expression of SMARCD3, CRIP2, PRAM1, HSPB2 and CERCAM in groups with different immune or stromal scores (A). Kaplan-Meier survival analysis based on expression value of these genes using TCGA COAD data (B–F).